Abdulraheem Yacoub, MD

Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could improve patient quality of life.

Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.

Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.

Abdulraheem Yacoub, MD, discusses imetelstat as a newer and exciting option for patients with myelodysplastic syndromes.

Abdulraheem Yacoub, MD, closes by sharing that the myelofibrosis treatment landscape is expected to evolve in the coming years with results to come from clinical trials investigating combination therapies, novel agents, and targeted approaches for disease progression and improving durability of response.

Severe anemia in myelofibrosis is defined as hemoglobin under 8 g/dL or transfusion dependence, requiring management with JAK inhibitors, erythropoietin stimulating agents, or danazol, given its impact on patient prognosis.

Dr Abdulraheem Yacoub discusses experience with the JAK inhibitor momelotinib in patients with myelofibrosis, noting robust efficacy in clinical trials for spleen volume reduction, symptom improvement, and anemia benefit, but explains that its utility in first-line versus second-line settings is still being determined.

Abdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.

Treatment goals for patients with myelofibrosis include prolonged survival and improved quality of life, with decision-making incorporating risk level, transplant eligibility, toxicity, and clinical trial data to select among the available JAK inhibitors.

Abdulraheem Yacoub, MD, provides an overview of myelofibrosis, including diagnosis via bone marrow examination, clinical criteria, and risk stratification using prognostic models to determine appropriate therapy.

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

Abdulraheem Yacoub, MD, offers closing thoughts on the future myelofibrosis treatment landscape, with a focus on treatments under investigation.

A detailed overview on monitoring patients with myelofibrosis, and signs that a treatment isn’t effective.

An expert on myelofibrosis discusses recently updated data on momelotinib, which was recently submitted for FDA approval.

Abdulraheem Yacoub, MD, details the systemic therapy options for myelofibrosis and his approach to treatment sequencing.

A myelofibrosis expert discusses the indications for treatment initiation and transplantation for patients with myelofibrosis.

An expert on myeloproliferative neoplasms gives an overview of myelofibrosis and assessing patient risk.

Abdulraheem Yacoub, MD, presents the case of a 68-year-old woman with myelofibrosis and offers his initial impressions.

Abdulraheem Yacoub, MD, associate professor of Hematology at the University of Kansas Cancer Center, discusses treatment beyond hydroxyurea in patients with polycythemia vera.<br /> &nbsp;